Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study

被引：35

作者：

Kita, Mariko ^{[1
]}

Fox, Robert J. ^{[2
]}

Phillips, J. Theodore ^{[3
]}

Hutchinson, Michael ^{[4
]}

Havrdova, Eva ^{[5
]}

Sarda, Sujata P. ^{[6
]}

Agarwal, Sonalee ^{[6
]}

Kong, Jessica ^{[6
]}

Zhang, Annie ^{[6
]}

Viglietta, Vissia ^{[6
]}

Sheikh, Sarah I. ^{[6
]}

Seidman, Emily ^{[7
]}

Dawson, Katherine T. ^{[6
]}

机构：

[1] Virginia Mason Med Ctr, Neurosci Inst, Seattle, WA 98101 USA

[2] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Dept Neurol, Cleveland, OH 44106 USA

[3] Baylor Inst Immunol Res, Multiple Sclerosis Program, Dallas, TX USA

[4] St Vincents Univ Hosp, Dept Neurol, Dublin 4, Ireland

[5] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic

[6] Biogen Idec Inc, Cambridge, MA USA

[7] CircleSci, Tytherington, England

来源：

MULTIPLE SCLEROSIS JOURNAL | 2014年 / 20卷 / 02期

关键词：

Multiple sclerosis; relapsing-remitting; BG-12; dimethyl fumarate; quality of life; glatiramer acetate; randomized controlled trial; PLACEBO-CONTROLLED PHASE-3; ORAL BG-12;

D O I：

10.1177/1352458513507818

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Multiple sclerosis (MS) has a significant impact on health-related quality of life (HRQoL) with symptoms adversely affecting many aspects of everyday living. BG-12 (dimethyl fumarate) demonstrated significant efficacy in the phase III studies DEFINE and CONFIRM in patients with relapsing-remitting MS. In CONFIRM, HRQoL was worse in patients with greater disability at baseline, and who relapsed during the study, and improved with BG-12 treatment. Mean Short Form-36 Physical Component Summary scores for BG-12 increased over 2 years and scores for placebo decreased. Coupled with clinical and neuroradiological benefits, these HRQoL results further support BG-12 as an effective oral treatment for relapsing MS.

引用

页码：253 / 257

页数：5

共 50 条

[31] Quality of life in relapsing-remitting multiple sclerosis patients receiving CinnoVex compared with Avonex [J].

Hatam, Nahid ;

Bastani, Peivand ;

Shahtaheri, Rahil Sadat .

JOURNAL OF RESEARCH IN PHARMACY PRACTICE, 2016, 5 (03) :181-185

[32] Predictors of quality of life in patients with relapsing-remitting multiple sclerosis: A 2-year longitudinal study [J].

Baumstarck, K. ;

Pelletier, J. ;

Boucekine, M. ;

Auquier, P. .

REVUE NEUROLOGIQUE, 2015, 171 (02) :173-180

[33] Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis [J].

Alroughani, Raed ;

Huppke, Peter ;

Mazurkiewicz-Beldzinska, Maria ;

Blaschek, Astrid ;

Valis, Martin ;

Aaen, Gregory ;

Pultz, Joe ;

Peng, Xiaomei ;

Beynon, Vanessa .

FRONTIERS IN NEUROLOGY, 2021, 11

[34] Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study [J].

Peter Joseph Jongen ;

Dirk Lehnick ;

Jan Koeman ;

Stephan Frequin ;

Dorothea Heersema ;

Bert Kornips ;

Angelique Schyns-Soeterboek ;

Leo H. Visser ;

Paul Schiphof ;

Anton Valkenburg ;

Johan Hiel .

Journal of Neurology, 2014, 261 :1469-1476

[35] Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study [J].

Jongen, Peter Joseph ;

Lehnick, Dirk ;

Koeman, Jan ;

Frequin, Stephan ;

Heersema, Dorothea ;

Kornips, Bert ;

Schyns-Soeterboek, Angelique ;

Visser, Leo H. ;

Schiphof, Paul ;

Valkenburg, Anton ;

Hiel, Johan .

JOURNAL OF NEUROLOGY, 2014, 261 (08) :1469-1476

[36] Establishing an Evaluation Scale for the Perception of Quality of Life Related to Relapsing-Remitting Forms of Multiple Sclerosis and Feasibility Study [J].

Baroin, A. ;

Mokadym, H. ;

Chopard, G. ;

Lavier, A. ;

Berger, E. ;

Rumbach, L. ;

Rude, N. .

INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2012, 122 (01) :9-16

[37] Impact of electroacupuncture on quality of life for patients with Relapsing-Remitting Multiple Sclerosis under treatment with immunomodulators: A randomized study [J].

Quispe-Cabanillas, Juan G. ;

Damasceno, Alfredo ;

von Glehn, Felipe ;

Brandao, Carlos O. ;

Damasceno, Benito P. ;

Silveira, Wanderley D. ;

Santos, Leonilda M. B. .

BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2012, 12

[38] Health-related quality of life in patients with multiple sclerosis [J].

Vazquez Gomez, Lazaro Aurelio ;

Hidalgo Mesa, Carlos ;

Beltran Gonzalez, Benita Mabel ;

Broche Perez, Yunier ;

Mederos Herrera, Ana Maria .

MEDISUR-REVISTA DE CIENCIAS MEDICAS DE CIENFUEGOS, 2022, 20 (01) :44-51

[39] High treatment adherence, satisfaction, motivation, and health-related quality of life with fingolimod in patients with relapsing-remitting multiple sclerosis - results from a 24-month, multicenter, open label Danish study [J].

Schreiber, Karen ;

Kant, Matthias ;

Pfleger, Claudia ;

Jensen, Henrik Boye ;

Oesterbergs, Ole ;

Hald, Anne Rieper ;

Nielsen, Frederik K. ;

Rubak, Sune .

PATIENT PREFERENCE AND ADHERENCE, 2018, 12 :1139-1150

[40] Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE [J].

Gold, Ralf ;

Arnold, Douglas L. ;

Bar-Or, Amit ;

Fox, Robert J. ;

Kappos, Ludwig ;

Chen, Chongshu ;

Parks, Becky ;

Miller, Catherine .

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2020, 13

← 1 2 3 4 5 →